Study on the Safety and Effectiveness of Bemcentinib with Pembrolizumab, Pemetrexed, and Carboplatin for Untreated Non-squamous Non-small Cell Lung Cancer

Sponsor: BerGenBio ASA

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05469178

Provider View

This clinical trial is testing a new combination of drugs, including bemcentinib, to see if they are safe and effective for treating adults with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have not received prior treatment.

Patient Parameters

Program Overview

The main goal of this study is to find out if a new combination of drugs, including bemcentinib, is safe and can help shrink tumors in patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have not been treated before. The study will also look at how well this combination works in patients with a specific genetic mutation called STK11, which is known to affect cancer growth.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or other treatments.
  • Have not received any previous treatment for advanced or metastatic NSCLC.
  • Have a type of NSCLC that does not have certain genetic changes that can be targeted by other treatments.
  • Have measurable cancer that can be tracked during the study.

Exclusion Criteria

  • Have received any previous chemotherapy or biological therapy for advanced or metastatic lung cancer.
  • Have specific genetic changes in the cancer, such as EGFR mutations or ALK rearrangements, that can be treated with other targeted therapies.
  • Have had radiation therapy within two weeks before starting the study treatment or have not fully recovered from side effects of previous radiation therapy.
  • Have had major surgery within 28 days before starting the study treatment and have not fully recovered from the surgery.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.